Stockscreener 앱 받기
2.32
3.11%
0.07
시장 영업 전:
2.32
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
MACD Signal: Can Editas Medicine Inc maintain sales growthEarnings Summary Report & Community Consensus Stock Picks - baoquankhu1.vn
How correlated is Editas Medicine Inc to the S P5002026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn
Q2 EPS Estimates for Editas Medicine Decreased by Analyst - MarketBeat
Zacks Research Weighs in on Editas Medicine FY2028 Earnings - MarketBeat
If You Invested $1,000 in Editas Medicine Inc (EDIT) - Stock Titan
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates - MSN
Editas Medicine, Inc. Trade Ideas — LS:A2AC4K - TradingView
RSI Check: Can Editas Medicine Inc outperform in the next rally2026 EndofMonth & High Accuracy Investment Signals - baoquankhu1.vn
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT) - The Globe and Mail
Institution Moves: Can Editas Medicine Inc disrupt its industry2026 News Drivers & Technical Pattern Based Buy Signals - baoquankhu1.vn
Editas Medicine (EDIT) Stock: 5-Year Valuation Drop & Recent Pipeline ChallengesNews and Statistics - IndexBox
Is Editas Medicine Going to $0? - The Globe and Mail
Can Editas Medicine Inc grow without external funding2026 Macro Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT) and Ascend Wellness Holdings LLC (OtherAAWH) - The Globe and Mail
Is Editas Medicine Headed Toward Zero? - Bitget
Editas Medicine (EDIT) grants 292,856 stock options to chief scientific officer - Stock Titan
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401 - MarketBeat
Editas Medicine at Barclays Conference: Strategic Focus on CRISPR Innovation - Investing.com Canada
Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects - TipRanks
Editas Medicine (EDIT) Receives Upgrade to 'Buy' from Jones Trad - GuruFocus
Editas Medicine (NASDAQ:EDIT) Upgraded at JonesTrading - MarketBeat
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - The Globe and Mail
Jones Trading upgrades Editas Medicine stock rating on gene therapy progress - Investing.com Canada
Editas Medicine 2025 Annual Report: CRISPR Gene Editing Pipeline, EDIT-401 Program, Intellectual Property, and Industry Competition - Minichart
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates - Bitget
Editas: Q4 Earnings Snapshot - theheraldreview.com
Cowen Maintains Buy on EDIT Editas Medicine, Inc. March 2026 - Meyka
Baird reiterates Editas Medicine stock rating on pipeline progress By Investing.com - Investing.com Canada
Editas Medicine 10-K: $40.5M revenue, $(1.80) EPS - TradingView
Editas Medicine (NASDAQ: EDIT) pivots to in vivo CRISPR and monetizes IP - Stock Titan
Editas Medicine (EDIT): Today's Analyst Rating Insights | EDIT S - GuruFocus
Editas Medicine (NASDAQ:EDIT) Receives "Buy" Rating from Chardan Capital - MarketBeat
TD Cowen reiterates Editas Medicine stock Buy rating on pipeline progress - Investing.com Canada
BREAKING: EDIT Reports Narrower Loss for Q4 EPS, vs. $0.21 per share estimated - AlphaStreet
Editas Medicine earnings beat by $0.17, revenue topped estimates - Investing.com Canada
Editas: Fourth Quarter Financial Overview - Bitget
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Editas Medicine Q4 2025 Financial Report: Loss of $5.6M, Revenue $24.7MNews and Statistics - IndexBox
Editas Medicine (EDIT) Reports Fourth Quarter Financials and Adv - GuruFocus
Editas Medicine posts fourth quarter and full year 2025 financial results - Traders Union
Editas Reports Q4 Earnings Beat - National Today
Editas Medicine stock rises 2% after Q4 earnings and revenue beats - Investing.com
Editas Medicine Q4 Earnings Beat Expectations - Intellectia AI
Editas Medicine (NASDAQ:EDIT) Announces Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
Editas Medicine posts smaller‑than‑expected Q4 net loss on lower R&D spend - TradingView
Editas Medicine SVP Parison sells $957 in stock By Investing.com - Investing.com Canada
Editas Medicine SVP Parison sells $957 in stock - Investing.com
Editas Medicine EVP Burkly sells $1.5k in stock - Investing.com UK
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,394 Shares - MarketBeat
Automatic tax-related share sale trims Editas (NASDAQ: EDIT) CEO stake - Stock Titan
1.82%
자본화:
|
볼륨(24시간):